cancer-immunotherapy

Documents about cancer-immunotherapy

• Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial#432896ClinicalTrials.gov
• Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial#262149HAL (France)
• Post-treatment serum interleukin-6 is independently associated with disease progression in patients with advanced non-small cell lung cancer and coexisting COPD: a multicenter real-world cohort study#673302ARPHA OAI-PMH Endpoint
• Neoplastic risk in hyperplastic esophagogastric junction lesions: Comprehensive multicenter study#176782HAL (France)
• Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology#407712ClinicalTrials.gov
• Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology#642180eScholarship
• Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer#279507ClinicalTrials.gov
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma#325290ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of D#164844Unpaywall
• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung#827967ClinicalTrials.gov
• Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer#344476HAL (France)
• The Next Frontier: Head and Neck Cancer Immunoprevention#614642eScholarship
• CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia#829817ClinicalTrials.gov
• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event#857835ClinicalTrials.gov
• Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies#865001ClinicalTrials.gov
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)#201773ClinicalTrials.gov
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)#807635ClinicalTrials.gov
• Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)#839229ClinicalTrials.gov
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study#411390ClinicalTrials.gov
• The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)#417530ClinicalTrials.gov
• Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma#848256ClinicalTrials.gov
• A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.#143556ClinicalTrials.gov
• Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer#784311eScholarship
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant#67875ClinicalTrials.gov
• An Antigen‐Delivery Protein Nanoparticle Combined with Anti‐PD‐1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model#619941eScholarship
• A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)#843087ClinicalTrials.gov
• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer#303731ClinicalTrials.gov
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer#683089ClinicalTrials.gov
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk#121342ClinicalTrials.gov
• Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology#161134Zenodo (CERN)
• Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8#614652eScholarship
• RNA-seq dataset: GB1275, a small-molecule agonist of cd11b, combined with drug-loaded oncolytic bacteria for pancreatic cancer therapy.#359847Figshare
• T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia#851126ClinicalTrials.gov
• Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer#127573ClinicalTrials.gov
• Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas#683887eScholarship
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study#123435ClinicalTrials.gov
• An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging#851159ClinicalTrials.gov
• PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol#630425HAL (France)
• Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers#675926eScholarship
• Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma#491856eScholarship
• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer#827648ClinicalTrials.gov
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies#279529ClinicalTrials.gov
• Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience / Manuel Weber, Leah Trumet, Fabienne Lange, Julia Murk, Philipp Schubert, Hasan Alsamra, Joy Backhaus, Stefanie Corradini, Marco Kesting, Sarina Müller, Joan Morris, Marlen Haderlein#675509Deutsche Nationalbibliothek
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)#870325ClinicalTrials.gov
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma#444887ClinicalTrials.gov
• A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma#863374ClinicalTrials.gov
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas#300255ClinicalTrials.gov
• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...#851674ClinicalTrials.gov
• A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab#828084ClinicalTrials.gov
• Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy / Anne-Laure Mallard de La Varende, Ai-Ling Tian, Simon Thomas, Imran Lahmar, Meriem Messaoudene, Sijing Li, Omar Motiño, Hortense Guillaume-dit-Taunière, Valerio Iebba, Yoan Hurtado, Thao-Nguyen Pham, Cassandra Thélémaque, Miguel Araujo-Voces, Deborah Suissa, Pierre Ly, Ella Reich, Giacomo Vitali, Bryan Thierry Arlunno, Sylvere Durand, Fanny Aprahamian, Marion Leduc, Sabrina Forveille, Oliver Kepp, Carlos de la Calle-Fabregat, Angela Schippers, Norbert Wagner, Pierre-Edouard Fournier, Kenya Honda, Federica Marmorino, Chiara Cremolini, Saman Maleki Vareki, John G. Lenehan, Aurélien Marabelle, François-Xavier Danlos, Margaux Deligne, Caroline Truntzer, François Ghiringhelli, Anne H. Ree, Paula A. Bousquet, Sebastian Meltzer, Florent Ginhoux, Deklan Rummel, Yousi Fu, Robert A. Quinn, Carolina Alves Costa Silva, Roberto Iacovelli, Chiara Ciccarese, Serena Porcari, Arielle Elkrief, Bertrand Routy, Gianluca Ianiro, Lisa Derosa, Guido Kroemer, Marine Fidelle, Laurence Zitvogel#780351Deutsche Nationalbibliothek